Related references
Note: Only part of the references are listed.HER2 as a limited predictor of the therapeutic response to neoadjuvant therapy in locally advanced rectal cancer
Mi Jung Kwon et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Rectal Cancer in Asian vs. Western Countries: Why the Variation in Incidence?
Yanhong Deng
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Bowel Dysfunction After Low Anterior Resection With Neoadjuvant Chemoradiotherapy or Chemotherapy Alone for Rectal Cancer: A Cross-Sectional Study from China
Qiyuan Qin et al.
DISEASES OF THE COLON & RECTUM (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Mismatch Repair Gene Expression as a Predictor of Tumor Responses in Patients With Rectal Cancer Treated With Preoperative Chemoradiation
Jung Wook Huh et al.
MEDICINE (2016)
Selective Approach for Upper Rectal Cancer Treatment: Total Mesorectal Excision and Preoperative Chemoradiation Are Seldom Necessary
Franco G. Marinello et al.
DISEASES OF THE COLON & RECTUM (2015)
Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
Xiangjiao Meng et al.
MEDICINE (2015)
KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery
Jeong Won Lee et al.
MEDICINE (2015)
Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium
Mary E. Charlton et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France
Frederique Penault-Llorca et al.
ANNALES DE PATHOLOGIE (2014)
HER2/neu testing in primary colorectal carcinoma
B. Ingold Heppner et al.
BRITISH JOURNAL OF CANCER (2014)
Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis
Xiangjiao Meng et al.
CANCER SCIENCE (2014)
Can a Biomarker-Based Scoring System Predict Pathologic Complete Response After Preoperative Chemoradiotherapy for Rectal Cancer?
Hyuk Hur et al.
DISEASES OF THE COLON & RECTUM (2014)
THE EFFECT OF TRANSVERSUS ABDOMINUS PLANE BLOCKS ON POSTOPERATIVE PAIN IN LAPAROSCOPIC COLORECTAL SURGERY: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL.
D. Keller et al.
DISEASES OF THE COLON & RECTUM (2014)
Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma
Marjun P. Duldulao et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study
S. Bregendahl et al.
COLORECTAL DISEASE (2013)
Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor
Sang-Woo Lim et al.
CELLULAR ONCOLOGY (2013)
Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years
Rolf Sauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer
Cecily P. Vaughn et al.
GENES CHROMOSOMES & CANCER (2011)
Mismatch repair status in sporadic colorectal cancer: Immunohistochemistry and microsatellite instability analyses
Yong Sik Yoon et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine
G. Smith et al.
BRITISH JOURNAL OF CANCER (2010)
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Manickam Janakiraman et al.
CANCER RESEARCH (2010)
Tissue microarray constructs to predict a response to chemoradiation in rectal cancer
Sergio Huerta et al.
DIGESTIVE AND LIVER DISEASE (2010)
Expression of HER2 in colorectal cancer does not correlate with prognosis
Wieslaw Janusz Kruszewski et al.
DISEASE MARKERS (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
Jochen Gaedcke et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive value of Ki67 and p53 in locally advanced rectal cancer: Correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy
Christiane Jakob et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
Federica Bertolini et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Recurrent KRAS Codon 146 mutations in human colorectal cancer
Sarah Edkins et al.
CANCER BIOLOGY & THERAPY (2006)
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy
Isrid Sturm et al.
BMC CANCER (2006)
The clinical importance and prognostic implications of microsatellite instability in sporadic cancer
DA Lawes et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2003)
Role of DNA mismatch repair defects in the pathogenesis of human cancer
P Peltomäki
JOURNAL OF CLINICAL ONCOLOGY (2003)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
p53 Gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
H Elsaleh et al.
ONCOLOGY (2000)
Share Paper
